The FT Global Pharmaceutical and Biotechnology Conference, now in its 35th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in this new era of unprecedented disruption and uncertainty.
FT Global Pharmaceutical and Biotechnology Conference
As old world certainties regarding payments, products and patients are swept away in a tidal wave of pricing pressures, growing geopolitical uncertainties and the new world realities of value, data and outcomes, life science companies will need to find new ‘ways to play’ if they are to adapt and compete in the new health economy which is emerging. Opportunities in the prevention, treatment and care of patients across key therapeutic areas including Alzheimer’s, cancer and other diseases of ageing, as well as the burgeoning field of precision medicine present opportunities, but can life science companies successfully play to their strengths in IP, regulation and high science to navigate the new terrain and ensure their place at the table?
Agenda - 9th Nov
9:00amOpening remarks from the Chair
9:30am‘Way to Play’: Embracing Strategic Opportunities in the New Health Economy
The recent history of pharma has been one of significant value destruction. Returns for shareholders look set to become in increasingly commensurate with those from commoditised industries – a position forecast only to intensify as pricing and other industry pressures start of bite. New ways to create value will need to be found if the industry is to continue to win favour with investors and strategies will need to be defined which will enable them to compete, to adapt and to embrace many of the new opportunities emerging in the new health economy. From high science, high premium and digitally enhanced business models to strategies based on developing off-the-shelf IP acquired from big pharma, what are the ‘ways to play’ to create value and growth in life sciences? What are the risk and opportunities in the various approaches?
10:10amGetting the Big Picture: Geopolitical and Economic Risk-What Lies Ahead?
From the backlash against globalisation and its impact on trade and global integrated supply chains to the decline economic growth and structural challenges in emerging markets-what is the industry vulnerability to geopolitical risk, and the macroeconomic exposure it faces? What are the external forces currently at play which will add considerably to the industry exposure to risk?
10:30amPanel: Trumpcare: What next for US Healthcare Reform?
With a new Administration in Washington pledging to overhaul the nation’s healthcare system, what will it mean for the life sciences and broader healthcare industry? Will we see Republicans successfully coalesce around an alternative healthcare reform proposal which will achieve the reported objectives of delivering improved choice, access and lower costs for patients? What will changes regarding insurance coverage, tax, immigration policies payment reform, trade and support for biomedical research, for instance, mean for the industry? What lies ahead for US healthcare reform in the months and years ahead, and how are healthcare and life science companies addressing this uncertainty?
11:10amNetworking Coffee Break
11:25amPanel: Adopting Open Innovation-Location, Strategies, Risks
Open innovation continues as a core strategy for life science companies in their drive to increase the productivity of their R&D. Location is key to the success of such efforts. For years, big pharma has been situated in fortress-like corporate campuses in places like New Jersey, Indiana and the Chicago suburbs. But increasingly, drugmakers are moving scientists to biotech clusters in coastal America and in Cambridge, UK. Here they can be close to the world's leading academic centres and younger drugmakers, guaranteeing access to early-stage science. What makes these "clusters" tick and what are the new hot areas to watch? Are clusters the best way to achieve enhanced collaboration? What are the opportunities, challenges and risks (e.g. IP) of open innovation? What are the lessons from early adapters and the outcomes?
12:05pmRight Sizing Regulation
As the debate regarding regulation moves centre stage with calls increasing for a loosening of regulation, speakers will discuss the pros and cons of less onerous regulation and drug approval. Are we seeing a politicisation of the debate of the drug approval process, with standards compromised and regulators ceding to patient pressures? As research breakthroughs continue to advance the boundaries of what’s possible in treatments, can we expect more coordinated campaigns as desperate patients strive to bend the regulatory rules rule in their favour? Or does regulation require a fundamental rethink? Should the focus be on safety, with efficacy left to doctors and patients?
1:50pmPricing and Access
Concerns regarding pricing and access remain central to the industry’s future profitability and sustainability. What are the emerging developments with regards to pricing, and potential solutions to the current impasse? Will self-regulation be sufficient? Will regulators, payers and patients continue to reward innovation?
2:30pmRealising the Potential of Real World Evidence (RWE)
As pharma companies continue to grapple with RWE, we hear from leaders in this field, who have developed end-to-end RWE capabilities, with insights into emerging best practice, and views on the remaining challenges in realising the full potential of RWE.
3:10pmThe Future for Innovation/R&D/Clinical Innovation/Clinical Trials
3:30pmPanel: Focus on Cancer
Given recent high profile knockbacks in trial results, what is the outlook for the burgeoning immuno-oncology space? Will the hopes for solutions in cancer combination therapies be realised? What are the prospects and challenges for emerging cancer therapies, to include CAR-T? As the level of competition in cancer therapies increases, will the field become increasingly commoditised? How could a growing focus on prevention, rather than cure impact financing and research on cancer?
3:50pmThe Trouble with Alzheimer’s: Transforming Treatment, Prevention and Care
Dementia-an ‘unstoppable epidemic, with Alzheimer’s at its core-is a leading cause of mortality in both the developed and developing world, and the enticing economics of ageing populations is drawing growing numbers of in pharmaceutical and healthcare compapaies into finding solutions the improve the treatment prevention and care of the disease. Yet progress has been slow, with no new treatments in a decade and recent drugs hailed to have promise failing in clinical trials. With the amyloid plaque theory now in doubt, is it time to evaluate alternative approaches, and which central theory is likely to guide further research efforts? Should the focus of research and investment now move to prevention? What are the innovations in diagnostics and technologies (e.g. robotics. AI.IoT, telecare etc.). prevention and care which could revolutionise the field?
4:30pmInvestor Panel: How do the Markets View the Future for the Industry?
In this final session of the day, our panel of leading investment bankers, venture capitalists and private equity specialists, and industry analysts share their views on how they see the sector changing and the potential headwinds and opportunities ahead.
5:10pmEnd of Day One
Agenda - 10th Nov
9:00amOpening remarks from the Chair
9:05amKeynote Address or Interview
9:30amPanel: Strategy Forum
In this session, our panel of Heads of Strategy /Chief Strategy Officers of leading pharma companies share their views on the megatrends ahead with the potential to further transform the industry.
10:10amPanel: How Will Precision Medicine Transform Healthcare and Life Sciences?
Precision medicine-the tailoring of medicine and healthcare to a person’s individual’s genes, lifestyle and environment- is making steady inroads, but how can the full potential of precision medicine be better harnessed, and its economic model and utility enhanced? With the more accurate diagnostics and the more precise disease classification precision medicine enables, what are the inplicatiions for drug research and for healthcare systems currently built around disease specific specialisations? As geneticists and computational experts take on a greater role, what will be the role for the physician? With more tailored and indivualised treatments, will life science companies successfully embrace opportunities emerging along the’ patient journey’? With the transition to value-based care models expedite the uptake of precision medicine?
11:00amFood as Medicine
As an understanding of the link between food and health and the role of the microbiome grows, food companies are moving into the field of therapeutic and personalised nutrition, and behaving increasing like drug companies through a focus on regulated products. What are the implications for life science companies? To what extent are these developments a threat or an opportunity to pharma? What are the prospects for personalised nutrition products based on gene/ biome type? Will food become a normal part of prescribing alongside pharmaceutical products?
11:40amNetworking Coffee Break
11:45amSocial Prescribing - The Next Big Thing?
With social prescribing playing an ever greater role in the medical professional’s toolbox, what are the implications for pharma? What is the evidence of the impact of social prescribing on health outcomes? Should health services pay? Will traditional drug based therapies and adhenance be compromised, with detrimental impacts on health?
12:30pmAging and Longevity
A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending healthspan -but also of studying the link between the processes of aging with a view to halting the onset of and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which aging could be viewed as just another disease to be ‘cured’, resulting in a less crippling and costly burden from age-related drug development and for care within the healthcare system. How far along are we in better understanding aging, and when might we see the testing and potential approval of anti-aging drugs in humans? What are the practical and philosophical challenges which need to be addressed before the development of anti-aging drugs arrives in earnest?
1:10pmDisrupt or Be Disrupted: The Big Digital Debate
Will pharma companies flourish or flounder in the new digitised healthcare world which is emerging? While pharma companies are recognising the value of digital products and services, their initiatives to date can appear as isolated beacons in a sea of change sweeping the healthcare industry. Will the industry be upended by data and consumer savvy new entrants who are impinging even into the core R&D business of pharma? Or will the industry traditional strengths in R&D, IP, risk management and complexity set them apart from the competition? Can they own and successfully navigate ‘the last mile’ to the customers ensure their place as winners in the hew health economy which is emerging?
1:40pmClosing Remarks from the Chair
1:45pmClose of Conference
- Review the diverse strategies life science companies are adopting to position themselves for growth and to navigate the emerging value and outcomes terrain
- Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures
- Hear from those who are turning the vision of personalised medicine into a clinical reality for patients today, and their views on the challenges ahead
- Discover how leading life science companies are managing economic uncertainty to capitalise on the value of high-potential emerging markets
- Gain critical insights in to new commercial models of pharma - what’s working and not working as value and personalisation upend traditional sales and marketing models
- Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical devices
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- Digital health companies
- Genomics and personalised medicine experts
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity and venture capitalists
- Healthcare lawyers and management consultants
- Patient representatives and NGOs
Lead Sponsor (1)
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON has built a reputation as an industry innovator and expert in transforming pharma R&D through strategic partnerships and alliances. The company’s expertise in managing and interpreting large clinical and real-world data sets has led to its selection by organisations involved in key transformative projects, including the 100,000 Genomes Project, the world’s largest genome sequencing project for cancer and rare diseases. ICON has also been chosen by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the creation of the world’s first global healthcare outcomes benchmarking program.
With headquarters in Dublin, Ireland, ICON currently operates from 88 locations in 37 countries and has approximately 12,600 employees. For further information please visit www.iconplc.com. Follow @iconplc on Twitter.
Associate Sponsor (1)
Pfizer is one of the world’s premier innovative biopharmaceutical companies, discovering, developing and providing over 120 different medicines, vaccines and consumer healthcare products to help save and improve the lives of millions of people in the UK and around the world every year.
222 Marylebone Road
London NW1 6JQ
United KingdomTel: +44 (0) 20 7631 8000